1 min read
SELLAS Life Sciences Shares Surge More Than 281% After Trial Results
The Phase 3 REGAL trial showed improved overall survival among patients with acute myeloid leukemia.

SELLAS Life Sciences shares surged more than 281% after the company announced positive results from its Phase 3 REGAL leukemia trial, which involved patients with acute myeloid leukemia.
SELLAS shares, which trade on Nasdaq as SLS, climbed above $28.
Trading volume exceeded 200 million shares.
The REGAL trial showed an improvement in overall survival among patients with acute myeloid leukemia.
The survival improvement was statistically significant.